Search the Library Catalogue
The Novartis Case: (Record no. 110640)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03874nam a2200217Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240323124549.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 180320s2008 xx 000 0 und d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | NLS |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Priyanka Mukherjee |
| 245 ## - TITLE STATEMENT | |
| Title | The Novartis Case: |
| Remainder of title | Confluence of Constitutional Law, International Trade and Innovation |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Bangalore |
| Name of publisher, distributor, etc. | NLSIU |
| Date of publication, distribution, etc. | 2008 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 124p |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Table of Contents<br/>I. Chapter I: Introduction: The Conceptual Base;<br/>• Compulsion to grant product patent;<br/>• Downsides of having drug patent;<br/>• India sharp to exploit TRIPS flexibilities;<br/>• Advantage India;<br/>• Formidable challenges faced by India;<br/>• Historical evolution of Indian patent law;<br/>• Pre- patent Act, 1970;<br/>• Salient features of Patent Act, 1970;<br/>• Post TRIPS era;<br/>II. Chapter II: The Constitutional Provisions of India- Received International Law (Article 51 (c))<br/>• Presumption is Parliament does not act in breach of International Law;<br/>• Implementation of treaty;<br/>• Non- incorporation and ratification;<br/>• Influence of International treaties over Indian law;<br/>III. Chapter III: The Patent Law in India;<br/>• The Patent (Amendment) Act, 1999;<br/>• The Patent (Amendment) Act, 2002;<br/>• The Patent (Amendment) Act, 2005;<br/>• The five important factors;<br/>IV. Chapter IV: MNCs v. Domestic companies;<br/>• The present pharmaceutical scenario;<br/>• The need for data protection;<br/>• Domestic companies;<br/>• Generic drug manufacturing units are here to stay;<br/>• Necessity for controlling prices of patented drugs;<br/>• Agrarian Economy;<br/>• Drug Price Controls;<br/>• Pharmaceutical drug production in India;<br/>V. Chapter V: Indian Patent Act, 1970- Analysis and Critique<br/>• Product patent for pharmaceutical substances;<br/>• Exclusions under the new law;<br/>VI. Chapter VI: Critical Analysis of the Patent (Amendment) Act, 2005;<br/>• New Invention;<br/>• The Inventive Step test;<br/>• Pharmaceutical substances;<br/>• New use exclusions;<br/>• Pre grant/ Post grant opposition;<br/>• Compulsory Licenses for exports;<br/>• Access to medicines;<br/>• Retrospective damages;<br/>• Patentability threshold;<br/>• Price Control/ competition regime;<br/>• Spurring an innovative culture in India;<br/>VII. Chapter VII: The Novartis Case: A study of specific<br/>• Jurisdiction to entertain petition;<br/>• Declaratory relief;<br/>• Uncanalized power to statutory authority;<br/>• Violation of Article 14;<br/>VIII. Chapter VIII: Glivec Patent Saga<br/>• Dissection of the Novartis judgment;<br/>• Selection Patent;<br/>• Glivec Patent Saga;<br/>• India's export led strategy;<br/>• Death by Patent Act;<br/>• TRIPS Agreement; Restrictions and Flexibilities;<br/>• Data exclusivity looms as an additional threat;<br/>IX. Chapter IX: Campaign to ensure public health protection;<br/>• Involvement of Indian pharmaceutical companies;<br/>• Successes and lessons learnt;<br/>• Exploitation of patent law loop holes;<br/>• Leaky protections: Section 107 A(b);<br/>X. Chapter X: Is Section 3(d) within TRIPS?;<br/>• Arguments for Section 3(d);<br/>• Arguments against Section 3(d);<br/>• Section 3(d) the structure and context;<br/>• Section 3( d) and TRIPS compatibility;<br/>XI. Chapter XI: TRIPS related issues;<br/>• Jurisdictional Issues- Ordinary contract or Treaty obligation;<br/>• TRIPS compatibility;<br/>• Fine balance maintained by Madras High Court;<br/>XII. Chapter XII: Constitutional Analysis of Section 3(d);<br/>• Manifest arbitrariness and Article 14;<br/>• Deconstruction the explanation to Section 3( d);<br/>• Defining efficacy;<br/>• Delegated legislation;<br/>• TRIPS paradox;<br/>XIII. Chapter XIII: Suggestions and Conclusions;<br/> |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Patent Law - Law, |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | TRIPS, |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Novartis Case - Access to Medicine |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Prof. T Devidas - Guide |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href=" http://opac.nls.ac.in:8081/xmlui/handle/123456789/1422"> http://opac.nls.ac.in:8081/xmlui/handle/123456789/1422</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Dissertation |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| National Law School | National Law School | 03.11.2017 | LLM211 | 20.03.2018 | 20.03.2018 | Dissertation |
Powered by Koha. Supported by focuzinfotech